English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/124602
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer

AuthorsPérez-Gómez, Eduardo ; Andradas, Clara; Caffarel, María M.; Villa-Morales, María ; Martín-Villar, Ester ; Flores, Juana María; Megías, Diego; Moreno-Bueno, Gema ; Quintanilla, Miguel ; Fernández-Piqueras, José ; Sánchez, Cristina
Issue Date2015
PublisherOxford University Press
CitationJournal of the National Cancer Institute 107(6): djv077 (2015)
Abstract[Background]: Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. [Methods]: We analyzed CB2 cannabinoid receptor protein expression in two series of 166 and 483 breast tumor samples operated in the University Hospitals of Kiel, Tübingen, and Freiburg between 1997 and 2010 and CB2 mRNA expression in previously published DNA microarray datasets. The role of CB2 in oncogenesis was studied by generating a mouse line that expresses the human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) rat ortholog (neu) and lacks CB2 and by a variety of biochemical and cell biology approaches in human breast cancer cells in culture and in vivo, upon modulation of CB2 expression by si/shRNAs and overexpression plasmids. CB2-HER2 molecular interaction was studied by colocalization, coimmunoprecipitation, and proximity ligation assays. Statistical tests were two-sided. [Results]: We show an association between elevated CB2 expression in HER2+ breast tumors and poor patient prognosis (decreased overall survival, hazard ratio [HR] = 0.29, 95% confidence interval [CI] = 0.09 to 0.71, P = .009) and higher probability to suffer local recurrence (HR = 0.09, 95% CI = 0.049 to 0.54, P = .003) and to develop distant metastases (HR = 0.33, 95% CI = 0.13 to 0.75, P = .009). We also demonstrate that genetic inactivation of CB2 impairs tumor generation and progression in MMTV-neu mice. Moreover, we show that HER2 upregulates CB2 expression by activating the transcription factor ELK1 via the ERK cascade and that an increased CB2 expression activates the HER2 pro-oncogenic signaling at the level of the tyrosine kinase c-SRC. Finally, we show HER2 and CB2 form heteromers in cancer cells. [Conclusions]: Our findings reveal an unprecedented role of CB2 as a pivotal regulator of HER2 pro-oncogenic signaling in breast cancer, and they suggest that CB2 may be a biomarker with prognostic value in these tumors.
Descriptionet al.
Publisher version (URL)http://dx.doi.org/10.1093/jnci/djv077
URIhttp://hdl.handle.net/10261/124602
DOI10.1093/jnci/djv077
Identifiersdoi: 10.1093/jnci/djv077
issn: 0027-8874
e-issn: 1460-2105
Appears in Collections:(IIBM) Artículos
(CBM) Artículos
Files in This Item:
File Description SizeFormat 
Cannabinoid receptor CB2.pdf2,7 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.